Sun Pharmaceutical Industries Q2FY18 in line; Recall of ANDAs could be precursor to resolution; Reduce | Sun Pharmaceutical Industries Q2FY18 | IndiaNotes.com


Sun pharma retains its guidance of single-digit decline in sales with 20-22% EBITDA margin. While SUNP had 20% effective tax rate in Q1FY18 and guided for higher tax rate in FY18E, they expects there could be lower tax rate with 10% and 14% tax rate in Q2FY18 and H1FY18.


Link to the PDF